| trial | Stage | No. of patients | arms | Lymphadenectomy | RFS (%) | OS (%) | Hazard ratio for OS (RFS if no OS) (95% CI) |
| INT-0116 [10] | pStage IB-IVA | 281 | I: Surgery + Leucovorin, fluorouracil + RT | D0/D1/D2 | - | ***36 | (C:I) 1.35 (1.09 - 1.66, P = 0.005) |
| 275 | C: Surgery alone | - | ***27 | ||||
| ACTS-GC [11] | pStage II/III | 529 | I: Surgery + S-1 | D2 | **65.4 | **71.7 | 0.669 (0.54 - 0.82) |
| 530 | C: Surgery alone | **53.1 | **61.1 | ||||
| CLASSIC [12] | pStage II/III | 520 | I: Surgery + CapOx | D2 | **68 | **78 | 0.66 (0.51 - 0.85) |
| 515 | C: Surgery alone | **53 | **69 | ||||
| JACCRO GC-07 [15] | pStage III | 454 | I: Surgery + DS | D2 | *50 | - | 0.63 (99.99% CI, 0.400 - 0.998) |
| 459 | C: Surgery alone | *66 | - | ||||
| JCOG1104 [14] | pStage II | 295 | C: Surgery + 8 courses SOX | D2 | *93.1 | - | 2.52 (1.11 - 5.77) |
|
|
| 295 | I: Surgery + 4 courses SOX | *89.8 | - | ||
| ARTIST 2 [16] | pStage II/III | 182 | I1: Surgery + S-1 | D2 | *64.8 | - | (I1:I2) 0.692 (P = 0.042) |
| 181 | I2: Surgery + SOX | *74.3 | - | (I2:I3) 0.971 (P = 0.879) | |||
| 183 | I3: Surgery + SOX + RT | *72.8 | - | (I1:I3) 0.724 (P = 0.074) | |||
| RESOLVE [18] | cStage III-IVA | 345 | C: Surgery + CapOx | D2 | *51.1 | - | - |
| 340 | I1: Surgery + SOX | *56.5 | - | 0.86 (0.68 - 1.07 P = 0.17) | |||
| 337 | I2: Preoperative SOX | *59.4 | - | 0.77 (0.61 - 0.97 P = 0.028) |